ArticleBMJ open2025
Burden of cancer attributable to sedentary behaviour in Germany: an epidemiological analysis of survey data.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global Research Trends and Hotspots in the Role of Cholesterol in Colorectal Cancer: A Bibliometric Analysis.Human mutation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSedentary behaviour (SB) is associated with increased risks of breast, colorectal, endometrial, ovarian and rectal cancers. However, the number of cancer cases attributable to SB in Germany and the associated costs are unknown.
settingNumbers and proportions (population-attributable fractions, PAF) of new cancer cases attributable to SB with published risk estimates for Germany for the years 2024, 2030 and 2040.
participantsSex-specific and age-specific population projections, national cancer incidence and exposure data. PRIMARY AND SECONDARY OUTCOME MEASURES: new cancer cases attributable to SB and healthcare costs associated with cancer cases attributable to SB in Germany for the year 2024.
resultsEstimated numbers of cancers attributable to SB are projected to be up to 7612 cases (6% of total cancer cases) in 2024, up to 7899 cases (6%) in 2030 and up to 8245 cases (6%) in 2040. The PAF attributable to SB in women is 3% for breast cancer, 8% for colon cancer, 9% for both endometrial and ovarian cancers and 2% for rectal cancer. In men, the PAF is 9% for colon cancer and 3% for rectal cancer. In 2024, the estimated costs of SB-attributable cancers are €270 million for colon cancer, €51 million for rectal cancer, €234 million for breast cancer and €242 million for female genital cancers.
conclusionsA considerable number of cancer cases can be attributed to SB, which also imposes a large health economic burden. Implementing effective prevention measures, such as workplace, school or commuting interventions, is needed to reduce the incidence of cancer attributable to this modifiable risk factor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.